Recently 45 Postdocs and PhD candidates attended the first Interactive career day organized by Janssen Pharmaceutica, to learn more about career perspectives and R&D activities that may lead to ideas and potential future collaboration on a longer term.
12 Participants were selected to showcase their research in a 3-minute pitch. All other participants were invited to present a poster. A jury selected the 3 best pitches and 3 best posters. These researchers will be invited to have an individual session with Janssen Pharmaceutica.
- Marilen Benner: Healthy uterus, healthy placenta, healthy offspring
- Jeroen Slaat: Tumor cells.
- Kinga Matula: Single-cell detection of metastatic cancer
- Michael Teders et al.: The Energy-Transfer-Enabled Biocompatible Disulfide-Ene Reaction
- Mike Marvin Ruth, Jodie Schilkraut et al.: A hollow-fiber infection model supported drug discovery pipeline for antmycobacterial drugs
- Elena Daines, Peer van Duppen: Chemical reaction networks in a dynamic environment
Related news items
Terrestrial bacteria can grow on nutrients from space26 May 2020
Researchers from the Radboudumc describe in an article in Astrobiology that bacteria can survive on an 'extraterrestrial diet', which affected their pathogenic potential.read more
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more